- Home
- PLSM vs ANTX Comparison
PLSM vs ANTX Comparison
Compare PLSM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSM | ANTX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5M | 36.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PLSM | ANTX |
|---|---|---|
| Price | $4.13 | $5.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 4.4K | ★ 3.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $1.00 |
| 52 Week High | $6.85 | $6.91 |
Technical Indicators
Market Signals| Indicator | PLSM | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 86.63 |
| Support Level | N/A | $1.05 |
| Resistance Level | $5.37 | N/A |
| Average True Range (ATR) | 0.37 | 0.68 |
| MACD | 0.04 | 0.46 |
| Stochastic Oscillator | 38.32 | 71.28 |
Price Performance
Historical ComparisonAbout PLSM Pulsenmore Ltd. Ordinary Shares
Pulsenmore Ltd is engaged in developing portable ultrasound devices for home use. Its ultrasound scanner dock's with patients' smartphones to deliver images that can be created anywhere, stored and forwarded for clinical review, or shared in an online consultation.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.